Please login to the form below
tenapanor
This page shows the latest tenapanor news and features for those working in and with pharma, biotech and healthcare.
FDA advisory committee recommends Ardelyx’s Xphozah for chronic kidney disease
The US Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has recommended Ardelyx’s Xphozah (tenapanor) for the control of serum phosphorus in adult patients with
Latest news
-
Ardelyx gets second kidney disease trial win for tenapanor
Tenapanor also achieved a 22%-24% reduction in levels of FGF23, a biomarker linked to an elevated risk of cardiovascular complications in CKD patients, compared to control. ... thinks tenapanor is “poised to be one of biotech's great product launches
-
Ardelyx buys back drug from AZ to 'accelerate development'
The two firms have been working on the NHE3 inhibitor tenapanor since 2012. ... which are conditions where we believe tenapanor could potentially transform the treatment paradigm," he said.
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
